Introduction: Remnant cholesterol (Rem-C) and triglyceride-rich lipoproteins (Rem-TRLp) increase risk for atherogenesis in adults but the concentrations and relationship with insulin resistance (IR) and subclinical inflammation in youth and young adults (YYA) is unclear.
Methods: We measured fasting lipoprotein particle size and number, GlycA (composite marker of inflammation), and lipoprotein insulin resistance index (LPIR) using NMR LipoProfile® in a pooled cohort analysis of 379 YYA: 64 healthy lean (HL), 163 healthy with BMI≥85th percentile (OWOB), 104 youth-type 2 diabetes (YT2D), and 48 lipodystrophy (LD). Rem-TRLp was calculated as small + very small TRLp and Rem-C as totalC — HDLC — LDLC). Regression models compared groups and determined relationships with LPIR and GlycA, adjusting for age, sex, and race/ethnicity.
Results: YYA were aged 17.1±4.3y (mean±SD), 62% female, 66% Black, BMI 31.7 ± 9.2 kg/m2. LPIR and GlycA were higher in LD and Y-T2D vs. OWOB and HL (Table). TRLp, Rem-C, and Rem-TRLp were highest in LD. Y-T2D had higher TRLp and Rem-TRLp vs. HL. Rem-C was related to LPIR and GlycA (both adjR2=0.5, P<0.01) and Rem-TRLP (both adjR2=0.2, P<0.01).
Conclusion: In YYA, Rem-C and Rem-TRLp associate with severe IR and inflammation. Their contribution to atherogenesis in high risk YYA with Y-T2D and LD requires further study.
A. Chowdhury: None. S.B. Glaros: None. M. Sampson: None. F. Davis: None. S.A. Dixon: None. A. Krenek: None. N. Malandrino: None. L. Mabundo: None. M. Lightbourne: None. R. Brown: Research Support; Regeneron Pharmaceuticals Inc., Pfizer Inc., Amryt Pharma Plc. S.N. Magge: None. S.T. Chung: None.
Intramural Research Program of the National Institute of Diabetes & Digestive & Kidney Diseases
